Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. It blocks viral entry into host cells while preserving normal immunologic function. The Company is also investigating an intramuscular method of administration of Trogarzo. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy.

TSX:TH - Post by User

Theratechnologies Inc > New PR aroundVM

<< Previous

Bullboard Posts

Next >>

Comment by SPCEO1on Oct 22, 2021 10:33am

151 Views

Post# 34037173

RE:RE:New PR aroundVM

Nobody is listening to what TH says. The few analysts still following the company got badly burned by by overly optimisitc Trogarzo and Egrifta sales expectations and have lost confidence in the company. The company's is currently targeting investors that really cannot invest in it much because of the sub-$5 stock price and small market cap. So, TH needs a better strategy if it wants to get better results for its share price. Investors need to have a sense that they will be missing out if they don't have a position established early in TH but that FOMO factor is non-existent with TH's stock, even though we are on the cusp of news that should have the FOMO factor operating at a high level.

Today's news is, in one sense, old news as they told the VM story at a cancer conference in June of 2020 (this si what led Soleus to get very interested in TH) but there is a whole lot of data in that article that looks to this non-scientist to be very important.